Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Ellis received his PhD at Australian National University Peter McCallum Cancer Center in 2008, after which he completed post-doctoral fellowships with Dr. Roberto Pili at Johns Hopkins University and Roswell Park Cancer Institute. After several years on the faculty of Roswell Park, he joined the faculty of Dana-Farber in 2017. His laboratory focuses on dissecting underlying genetic and epigenetic mechanisms of initiation and progression of aggressive cancer, with emphasis on prostate cancer.
Work within my laboratory focuses on dissecting underlying genetic/epigenetic mechanisms of initiation and progression of aggressive cancer, with emphasis on prostate cancer. Our overall goal is to identify novel genomic/epigenomic mechanisms that will lead to discovery of biomarkers and therapeutic targets for clinical testing. Our major projects include identifying genetic drivers and novel biomarkers of aggressive prostate cancer, exploiting Rb1 deficiency for treatment of lethal neuroendocrine prostate cancer, and generation and utility of murine and human organoid bio-banks.
450 Brookline AvenueBurlington Avenue 446Boston MA, 02215Get Directions